Director at Cogent Biosciences (NASDAQ: COGT) receives 17,901 stock options

Rhea-AI Filing Summary

Cogent Biosciences director Todd Shegog received a new stock option award covering 17,901 shares of common stock. The options have an exercise price of $31.98 per share and expire on June 9, 2036. This grant increases his direct derivative holdings to 17,901 option shares.

The option will vest in full on the earlier of the first anniversary of the grant date or the date of the company’s 2027 Annual Meeting of Stockholders, provided Shegog continues to serve the company through that date. Until vesting and exercise, the award represents potential, not current, share ownership.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Shegog Todd

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	17,901	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 17,901 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Option grant size: 17,901 shares Exercise price: $31.98 per share Expiration date: June 9, 2036 +1 more

4 metrics

Option grant size 17,901 shares Stock options granted to director on June 9, 2026

Exercise price $31.98 per share Strike price for the 17,901 stock options

Expiration date June 9, 2036 Option term for director grant

Post-grant derivative holdings 17,901 option shares Total derivative securities following this grant

Key Terms

Stock Option (Right to Buy), exercise price, Annual Meeting of Stockholders, vesting

4 terms

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

exercise price financial

"conversion_or_exercise_price: "31.9800""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

Annual Meeting of Stockholders financial

"the date of the 2027 Annual Meeting of Stockholders"

vesting financial

"This stock option shall vest in full upon the earlier of the first anniversary"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Shegog Todd

(Last) (First) (Middle)

C/O COGENT BIOSCIENCES, INC.

180 THIRD AVENUE, 4TH FLOOR

(Street)

WALTHAM MASSACHUSETTS 02451

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Cogent Biosciences, Inc. [ COGT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$31.98	06/09/2026		A		17,901		(1)	06/09/2036	Common Stock	17,901	$0	17,901	D

Explanation of Responses:

1. This stock option shall vest in full upon the earlier of the first anniversary of the date of grant or the date of the 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer through such date.

	/s/ Evan D. Kearns, Attorney-in-Fact	06/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Todd Shegog report in his latest Form 4 for COGT?

Todd Shegog reported receiving a stock option grant for 17,901 shares of Cogent Biosciences common stock. The options are a compensation-related award, not an open-market purchase or sale of existing shares.

How many Cogent Biosciences options did Todd Shegog receive?

Todd Shegog received stock options covering 17,901 shares of Cogent Biosciences common stock. These options give him the right to buy shares in the future once they vest and are exercised, subject to the grant’s terms.

What is the exercise price of Todd Shegog’s Cogent Biosciences options?

The exercise price of Todd Shegog’s stock options is $31.98 per share. This is the price he must pay to purchase Cogent Biosciences common stock once the options vest and he chooses to exercise them, before their expiration date.

When do Todd Shegog’s Cogent Biosciences options vest?

The options vest in full on the earlier of the first anniversary of the grant date or the 2027 Annual Meeting of Stockholders. Vesting is contingent on Todd Shegog’s continued service with Cogent Biosciences through that vesting date.

When do Todd Shegog’s Cogent Biosciences stock options expire?

Todd Shegog’s stock options expire on June 9, 2036. If he does not exercise the options by that expiration date, they lapse and can no longer be used to purchase Cogent Biosciences common shares under this grant.

Is Todd Shegog’s Form 4 for COGT an open-market trade?

No, the Form 4 reflects a grant of stock options as compensation, coded as an acquisition (A). It does not involve an open-market purchase or sale of Cogent Biosciences shares, but rather an award of rights to buy shares later.